Table 2.
In vitro antimicrobial resistance rates of major Gram-negative bacteria (E. coli, K. pneumoniae, P. aeruginosa) from 2016 to 2019 (%)
| AMK | ATM | CAZ | COL | CRO | ETP | FEP | FOX | IPM | LVX | MEM | TOB | TZP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E. coli (n = 284) | 7 (2.5%) | 51 (45.5%) | 88 (31.0%) | 16 (5.6%) | 162 (57.0%) | 12 (4.2%) | 127 (44.7%) | 46 (16.2%) | 8 (2.8%) | 161 (56.7%) | 9 (3.2%) | - | 26 (9.2%) |
| 2016 (n = 57） | 3 (5.3%) | 10 (47.6%) | 27 (47.4%) | 5 (8.8%) | 41 (71.9%) | 5 (8.8%) | 37 (64.9%) | 15 (26.3%) | 4 (7.0%) | 35 (61.4%) | 5 (8.8%) | - | 10 (17.5%) |
| 2017 (n = 79) | 2 (2.5%) | 13 (50.0%) | 16 (20.3%) | 5 (6.3%) | 39 (49.4%) | 4 (5.1%) | 33 (41.8%) | 16 (20.3%) | 3 (3.8%) | 43 (54.4%) | 3 (3.8%) | - | 7 (8.9%) |
| 2018 (n = 69) | 1 (1.4%) | 17 (48.6%) | 20 (29.0%) | 3 (4.3%) | 38 (55.1%) | 2 (2.9%) | 26 (37.7%) | 7 (10.1%) | 1 (1.4%) | 39 (56.5%) | 1 (1.4%) | - | 5 (7.2%) |
| 2019 (n = 79) | 1 (1.3%) | 11 (36.7%) | 25 (31.6%) | 3 (3.8%) | 44 (55.7%) | 1 (1.3%) | 31 (39.2%) | 8 (10.1%) | 0 (0.0%) | 44 (55.7%) | 0 (0.0%) | - | 4 (5.1%) |
| K. pneumoniae (n = 171) | 30 (17.5%) | 125 (44.0%) | 63 (36.8%) | 11 (6.4%) | 76 (44.4%) | 49 (28.7%) | 63 (36.8%) | 66 (38.6%) | 44 (25.7%) | 69 (40.4%) | 43 (25.1%) | - | 50 (29.2%) |
| 2016 (n = 31) | 7 (22.6%) | 35 (61.4%) | 11 (35.5%) | 3 (9.7%) | 14 (45.2%) | 11 (35.5%) | 11 (35.5%) | 13 (41.9%) | 8 (25.8%) | 14 (45.2%) | 8 (25.8%) | - | 8 (25.8%) |
| 2017 (n = 42) | 8 (19.0%) | 26 (32.9%) | 19 (45.2%) | 2 (4.8%) | 23 (54.8%) | 13 (31.0%) | 22 (52.4%) | 20 (47.6%) | 13 (31.0%) | 20 (47.6%) | 13 (31.0%) | - | 15 (35.7%) |
| 2018 (n = 54) | 7 (13.0%) | 29 (42.0%) | 16 (29.6%) | 3 (5.6%) | 23 (42.6%) | 10 (18.5%) | 16 (29.6%) | 14 (25.9%) | 10 (18.5%) | 19 (35.2%) | 9 (16.7%) | - | 10 (18.5%) |
| 2019 (n = 44) | 8 (18.2%) | 35 (44.3%) | 17 (38.6%) | 3 (6.8%) | 16 (36.4%) | 15 (34.1%) | 14 (31.8%) | 19 (43.2%) | 13 (29.5%) | 16 (36.4%) | 13 (29.5%) | - | 17 (38.6%) |
| P. aeruginosa (n = 112) | 15 (13.4%) | 51 (45.5%) | 39 (34.8%) | 13 (11.6%) | N | N | 37 (33.0%) | N | 44 (39.3%) | 41 (36.6%) | 40 (35.7%) | 7 (10.8%) | 42 (37.5%) |
| 2016 (n = 21) | 4 (19.0%) | 10 (47.6%) | 9 (42.9%) | 2 (9.5%) | N | N | 7 (33.3%) | N | 11 (52.4%) | 6 (28.6%) | 9 (42.9%) | - | 10 (47.6%) |
| 2017 (n = 26) | 5 (19.2%) | 13 (50.0%) | 11 (42.3%) | 1 (3.8%) | N | N | 11 (42.3%) | N | 9 (34.6%) | 12 (46.2%) | 9 (34.6%) | - | 9 (34.6%) |
| 2018 (n = 35) | 3 (8.6%) | 17 (48.6%) | 10 (28.6%) | 5 (14.3%) | N | N | 12 (34.3%) | N | 15 (42.9%) | 15 (42.9%) | 15 (42.9%) | 5 (14.3%) | 13 (37.1%) |
| 2019 (n = 30) | 3 (10.0%) | 11 (36.7%) | 9 (30.0%) | 5 (16.7%) | N | N | 7 (23.3%) | N | 9 (30.0%) | 8 (26.7%) | 7 (23.3%) | 2 (6.7%) | 10 (33.3%) |
N natural drug resistance, -, no detection
Abbreviations: AMK amikacin, ATM aztreonam, CAZ ceftazidime, COL colistin, CRO ceftriaxone, ETP ertapenem,FEP cefepime, FOX cefoxitin, IPM imipenem, LVX levofloxacin, MEM meropenem, TOB tobramycin, TZP piperacillin-tazobactam